Studying the effects of new peritoneal dialysis solutions on the peritoneum

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Chan, Tak Mao ^a,b   Yung, Susan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Amino acid; Bicarbonate; Glucose; Icodextrin; Peritoneum

Indexed keywords

AMINO ACID; BICARBONATE; DIALYSIS FLUID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; GROWTH FACTOR; ICODEXTRIN; LACTIC ACID; WATER;

BIOCOMPATIBILITY; CLINICAL STUDY; CONFERENCE PAPER; DIALYSATE; HUMAN; HYALINE DEGENERATION; IN VITRO STUDY; LEUKOCYTE FUNCTION; LONG TERM EXPOSURE; MACROPHAGE; MALNUTRITION; MEMBRANE TRANSPORT; MESOTHELIUM; MESOTHELIUM CELL; MORBIDITY; MORTALITY; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PHAGOCYTOSIS; PRIORITY JOURNAL; SOLUTE; ULTRAFILTRATION; WATER TRANSPORT;

AMINO ACIDS; ANIMALS; BICARBONATES; BIOCOMPATIBLE MATERIALS; BUFFERS; DIALYSIS SOLUTIONS; GLUCANS; GLUCOSE; HUMANS; PERITONEAL DIALYSIS; PERITONEUM;

EID: 35748986444     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Parikova A, Smit W, Struijk DG, Krediet RT. Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure. Kidney Int 2006; 70:1988-94.
2. Gokal R. Long term peritoneal dialysis - is it a reality? J Nephrol 1999; 12:362-70.
3. Flessner MF. The effect of fibrosis on peritoneal transport. Contrib Nephrol 2006; 150:174-80.
4. Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
5. Williams JD, Craig KJ, von Ruhland C, Topley N, Williams G, for the Biopsy Registry Study Group. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int 2003; 64(Suppl 88):S43-9.
6. Williams JD, Craig KJ, Topley N, Williams GT. Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney Int 2003; 63(Suppl 84):S158-61.
7. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9:41-5.
8. Gotloib L, bar-Sella P, Shostak A. Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum: ultrastructural changes of reduplicated peritoneal basement membrane. Perit Dial Bull 1985; 5:212-14.
9. Dobbie JW, Lloyd JK, Gall CA. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 1990; 6:3-12.
10. Holmes CJ, Shockley TR. Strategies to reduce glucose exposurein peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2):S37-41.
11. Pennell P, Rojas C, Asif A, Rossini E. Managing metabolic complications of peritoneal dialysis. Clin Nephrol 2004; 62:35-43.
12. Feriani M. Use of different buffers in peritoneal dialysis. Sernin Dial 2000; 13:256-60.
13. Wong T, Phillips AO, Witowski 3, Topley N. Glucose-mediated induction of TGF-β1 and MCP-1 in mesothelial cells is osmolality and polyol pathway dependent. Kidney Int 2003; 63:1404-16.
14. Ing TS, Yu AW, Podila PV, Zhou FQ, Kun EW, Strippoli P, et al. Failure of neutrophils to recover their abitity to produce superooxide after stunning by a conventional, addic, lactate-based peritoneal dialysis solution. Int J Artif Organs 1994; 17:191-4.
15. Tian XK, Shan YS, Zhe XW, Cheng LT, Wang T. Metabolic acidosis is peritoneal dialysis patients: the role of residual renal function. Blood Purif 2005; 23:459-65.
16. Stein A, Moorhouse J, Iles-Smith H, Baker F, Johnstone J, James G, et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997; 52:1089-95.
17. Holmes CJ, Faict D. Peritoneal dialysis solution biocompatibility: definitions and Evaluation strategies. Kidney Int 2003; 64(Suppl 88):S50-6.
18. ter Wee PM, Beeten RHJ, van den Born J. The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions. Kidney Int 2003; 64:S75-83.
19. Krediet RT, Zweers MM, van Westrhenen R, Ho-dac-Pannekeet MM, Struijk DG. What can we do to preserve the peritoneum? Perit Dial Int 2003; 23(Suppl 2):S14-19.
20. Di Paolo N, Garosi G, Petrini G, Traversari L, Rossi P. Peritoneal dialysis solution biocompatibility testing in animals. Perit Dial Int 1995; 15:S61-9.
21. Hoff CM. In vitro biocompatibility performance of Physioneal. Kidney Int 2003; 64:S57-74.
22. Rogachev B, Hausmann MJ, Yulzari R, Weiler M, Holmes C, Faict D, et al. Effect of bicarbonate-based dialysis solutions on intracellular pH (pHi) and TNFα production by peritoneal macrophages. Perit Dial Int 1997; 17:546-53.
23. Sundaram S, Cendoroglo M, Cooker LA, Jaber BL, Faict D, Holmes CJ, et al. Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral blood mononudear cell and polymorphonuclear cell function in vitro. Am J Kidney Dis 1997; 30:680-9.
24. Ogata S, Naito T, Yorioka N, Kiribayashi K, Kuratsune M, Kohno N. Effect of lactate and bicarbonate on human peritoneal mesothelial cells, fibroblasts and vascular endothelial cells, and the role of basic fibroblast growth factor. Nephrol Dial Int 2004; 19:2831-7.
25. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw I, et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/ lactate-buffered solution. J Am Sac Nephrol 2001; 12:2775-86.
26. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions. Effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
27. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67:1559-65.
28. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranæus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen CA125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
29. Vardan A, Zweers MM, Gokal R, Krediet RT. A solution portfolio approach in peritoneal dialysis. Kidney Int 2003; 64(Suppl 88):S114-23.
30. Garosi G, Gaggiotti E, Monad G, Brardi S, Di Paolo N. Biocompatibility of a peritoneal dialysis solution with amino acids: histological Evaluation in the rabbit. Peril Diel Int 1998; 18:610-19.
31. Chan TM, Leung JKH, Sun Y, Lai KN, Tsang RCW, Yung S. Different effects of amino acid-based and glucose-based dialysate from peritoneal dialysis patients on mesothelial cell ultrastructure and function. Nephrol Dial Transplant 2003; 18:1086-94.
32. Zareie M, van Lambalgen AA, ter Wee PM, Hekking LH, Keuning ED, Schadee-Eestermans IL, et al. Better preservation of the peritoneum in rats exposed to amino add-based peritoneal dialysis fluid. Peril Diol Int 2005; 25: 58-67.
33. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 1998; 32: 761-9.
34. Li FK, Chan LY, Woo JC, Ha SK, Lo WK, Lai KN, et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003; 42:173-83.
35. Alsop RM. History, chemical and pharmaceutical development of icodextrin. Perit Dial Int 1994; 14:S5-12.
36. Thomas S, Schenk U, Fischer FP, Mettang T, Passlick-Deetjen J, Kuhlmann U. In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytotic activity. Am J Kidney Dis 1997; 29:246-53.
37. Bajo MA, Selgas R, Castro MA, del Peso G, Diaz C, Sanchez-Tomero JA, et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human peritoneal mesothelial cells studied ex vivo. Perit Dial Int 2000; 20: 742-7.
38. Ha H, Yu MR, Choi HN, Cha MK, Kang HS, Kim NH, et al. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int 2000; 20:10-18.
39. Gotloib L, Wajsbrot V, Shostak A. Mesothelial dysplastic changes and lipid peroxidation induced by 7.5% icodextrin. Nephron 2002; 92:142-55.
40. Parikova A, Zweers MM, Struijk DG, Krediet RT. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 2003; 19:186-90.
41. Martikainen TA, Teppo AM, Gronhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25:453-60.
42. Gokal R, Mistry CD, Peers EM. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Mutticenter Investigation of Icodextrin in Ambulatory Dialysis. Perit Dial Int 1995; 15:226-30.
43. Witkie M, Plant M, Edwards L, Brown C. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Peril Dial Int 1997; 17:84-6.